Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 3/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 2/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390069 | 1.00 | RXRA (0.51) | RXRARXRBRXRGIRAK4CYP4F2 | |
| SCHEMBL2144475 | 0.91 | IRAK4 (0.47) | RXRARXRBRXRGIRAK4CYP4F2 | |
| SCHEMBL29741019 | 0.91 | IRAK4 (0.47) | RXRARXRBRXRGIRAK4CYP4F2 | |
| SCHEMBL17678315 | 0.82 | IRAK4 (0.44) | IRAK4HIF1ATNKSLPLLIPG | |
| SCHEMBL30242559 | 0.82 | CYP4F2 (0.38) | RXRARXRBRXRGIRAK4CYP4F2 | |
| SCHEMBL12370610 | 0.82 | CYP4F2 (0.38) | RXRARXRBRXRGIRAK4CYP4F2 | |
| SCHEMBL17678304 | 0.82 | IRAK4 (0.46) | IRAK4TNKSLPLLIPG | |
| SCHEMBL24153533 | 0.81 | RXRA (0.43) | RXRARXRBRXRGIRAK4CYP4F2 | |
| SCHEMBL20424091 | 0.81 | RXRA (0.43) | RXRARXRBRXRGIRAK4CYP4F2 | |
| SCHEMBL18480146 | 0.81 | CYP4F2 (0.39) | RXRARXRBRXRGIRAK4CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2024040768-A1 | 5-PYRIDINE-1H-INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE | 中国药科大学 | 2024-02-29 | — | — | WO | disclosed |
| US-20230219956-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | BETTA PHARMACEUTICALS CO.,LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2023122600-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20220281821-A1 | INDAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS | JINAN UNIVERSITY (CN) | 2022-09-08 | — | — | US | disclosed |
| CN-114072387-A | Indazole compound and medicinal composition and application thereof | 暨南大学 | 2022-02-18 | — | — | CN | disclosed |
| EP-3746079-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | Bayer Aktiengesellschaft (DE) | 2020-12-09 | — | — | EP | disclosed |
| CN-112040951-A | Antibody Drug Conjugates (ADC) with NAMPT inhibitors | 拜耳股份公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20130203702-A1 | HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2013-08-08 | — | — | US | disclosed |
| US-20130203702-A1 | HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2013-08-08 | — | — | US | disclosed |
| EP-2257545-B1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| EP-2257545-B1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMAN-LA ROCHE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMAN-LA ROCHE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMAN-LA ROCHE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2257545-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009115427-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009115427-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203702-A1 | HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | FDPS, GGPS1, PPA1 | RXRA 1547/4885RXRB 1357/4885RXRG 1639/4885 |
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | SLC6A3, MAOB, TPH2 | RXRA 3262/4885RXRB 3254/4885RXRG 3166/4885 |
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | RXRA 129/4885RXRB 115/4885RXRG 96/4885 |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, STAT1, STAT5B | RXRA 81/4885RXRB 61/4885RXRG 48/4885 |
| US-20230219956-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCG2, NQO2 | RXRA 4148/4885RXRB 4049/4885RXRG 4083/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | RXRA 76/4885RXRB 83/4885RXRG 113/4885 |
| US-20220281821-A1 | INDAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS | TNK2, TNNI3K, CSNK1G3 | RXRA 2973/4885RXRB 2130/4885RXRG 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.